New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,352.05 0.40 +0.03%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Eli Lilly and Company (LLY) revenue by segment, product and region

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.